Bioventus Inc.
BVS
$9.15
-$0.36-3.79%
| 12/31/2024 | 09/28/2024 | 06/29/2024 | 03/30/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 153.64M | 138.96M | 151.22M | 129.46M | 135.42M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 153.64M | 138.96M | 151.22M | 129.46M | 135.42M |
| Cost of Revenue | 50.99M | 45.41M | 47.58M | 41.08M | 49.12M |
| Gross Profit | 102.66M | 93.55M | 103.64M | 88.38M | 86.30M |
| SG&A Expenses | 86.53M | 81.04M | 82.28M | 78.41M | 78.36M |
| Depreciation & Amortization | 1.77M | 2.07M | 2.06M | 1.76M | 2.10M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 142.53M | 132.33M | 135.91M | 123.84M | 132.84M |
| Operating Income | 11.11M | 6.64M | 15.30M | 5.62M | 2.58M |
| Income Before Tax | 232.00K | -4.83M | -39.45M | -5.08M | -8.41M |
| Income Tax Expenses | 550.00K | 589.00K | -7.34M | 907.00K | -750.00K |
| Earnings from Continuing Operations | -318.00K | -5.42M | -32.11M | -5.98M | -7.66M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | 0.00 |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 162.00K | 597.00K | 8.12M | 1.41M | 1.56M |
| Net Income | -156.00K | -4.82M | -23.99M | -4.57M | -6.10M |
| EBIT | 11.11M | 6.64M | 15.30M | 5.62M | 2.58M |
| EBITDA | 15.90M | 18.91M | 28.39M | 17.41M | 9.29M |
| EPS Basic | 0.00 | -0.07 | -0.37 | -0.07 | -0.10 |
| Normalized Basic EPS | 0.03 | -0.01 | 0.18 | -0.02 | -0.04 |
| EPS Diluted | 0.00 | -0.07 | -0.37 | -0.07 | -0.10 |
| Normalized Diluted EPS | 0.03 | -0.01 | 0.18 | -0.02 | -0.04 |
| Average Basic Shares Outstanding | 65.45M | 65.26M | 64.06M | 63.38M | 63.10M |
| Average Diluted Shares Outstanding | 65.45M | 65.26M | 64.06M | 63.38M | 63.10M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
